|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | UNITED      STATESSECURITIES      AND EXCHANGE COMMISSIONWashington,      D.C. 20549                       |                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                            | FORM      10-Q                                                                      |   |   |
| (Mark      One)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                            |                                                                                     |   |   |
| xQUARTERLY REPORT PURSUANT TO      SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF      1934For      the quarterly period ended September 30, 2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                            | OR                                                                                  |   |   |
| [ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES      EXCHANGEACT      OF 1934 For the transition period from __________ to      ___________                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                            | Commission      File Number 333-150483                                         |   |   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                            | Noble Medical Technologies,      Inc.(Name      of small business issuer in its charter) |   |   |
| Delaware                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                            | 20-0587718                                                                          |
| (State      or Other Jurisdiction ofIncorporation      or Organization)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (I.R.S.      Employer Identification No.)                                                                       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 4430      Noble Avenue – Apartment 201Sherman Oaks, CA 91403(Address      of Principal Executive Offices) |                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                            |  310-498-0778(Issuer's      Telephone Number, Including Area Code)             |   |   |
|  Check whether the issuer (1)      filed all reports required to be filed by Section 13 or 15(d) of the      Exchange Act during the past 12 months (or for such shorter period that      the registrant was required to file such reports), and (2) has been      subject to such filing requirements for the past 90 days. YESxNO o Indicate      by check mark whether the registrant is a large accelerated filer, an      accelerated filer, a non-accelerated filer or a smaller reporting company      filer.  See definition of “accelerated filer” and “large      accelerated filer” in Rule 12b-2 of the Exchange Act (Check      one): Large Accelerated Filero   Accelerated Filero       Non-Accelerated Filero       Smaller Reporting      Companyx Indicate by check mark whether      the registrant is a shell company (as defined in Rule 12b-2 of the      Exchange Act). YES x NOo  |
| State      the number of shares outstanding of each of the issuer’s classes of common      equity, as of the latest practicable date: 4,188,000 shares of common      stock, par value $.0001 per share, as of November 13, 2008. Transitional Small Business      Disclosure Format (Check one). YES o NOx                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                            |                                                                                     |   |   |   |   |   |   |

----

| Balance      Sheets at September 30, 2008 ( Unaudited) and December 31,      2007                                                                                                                                                                             | F-2              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Statements      of Operations for the Three Months Ended September 30, 2008 and for the      Period from July 25, 2007 (Inception) through September 30, 2007      (Unaudited)                                                                                | F-3              |
| Statements      of Operations for the Nine Months Ended September 30, 2008, for the Period      from July 25, 2007 (Inception) through September 30, 2007, and for the      Period from July 25, 2007 (Inception) through September 30, 2008      (Unaudited) | F-4              |
| Statement      of Stockholders’ Deficit for the Period from July 25, 2007 (Inception)      through September 30, 2008 (Unaudited)                                                                                                                       | F-5              |
| Statement      of Cash Flows for the Nine Months Ended September 30, 2008, for the Period      from July 25, 2007 (Inception) through September 30, 2007, and for the      Period from July 25, 2007 (Inception) through September 30, 2008      (Unaudited)  | F-6              |
| Notes      to the Financial Statements (Unaudited)                                                                                                                                                                                                            | F-7      to F-10 |

----

| NOBLE      MEDICAL TECHNOLOGIES, INC.                                    |                    |
|--------------------------------------------------------------------------|-------------------------|
| (A      DEVELOPMENT STAGE COMPANY)                                       |                    |
| BALANCE      SHEETS                                                      |                    |
|                                                                     |                    |   |   |   |   |   |   |   |
|                                                                     |                    |   |   |   |   |   |   |   |
|                                                                     |                    |   |   |   |   |   |   |   |
|                                                                     |                    |   |   |   |   |   |   |   |
|                                                                     | September      30, 2008 |   | December      31, 2007 |   |
|                                                                     | (Unaudited)             |   |   |   |   |   |
|  ASSETS                                                             |                    |   |   |   |   |   |   |   |
|  CURRENT      ASSETS:                                               |                    |   |   |   |   |   |   |   |
| Cash                                                                     |                    |   |   | $371 |   |   |   |   | $2,093 |   |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
| Total      Current Assets                                                |                    |   |   | 371 |   |   |   |   | 2,093 |   |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
| Total      Assets                                                        |                    |   |   | $371 |   |   |   |   | $2,093 |   |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
|  LIABILITIES      AND STOCKHOLDERS' DEFICIT                         |                    |   |   |   |   |   |   |   |   |   |
|  CURRENT      LIABILITIES:                                          |                    |   |   |   |   |   |   |   |   |   |
| Accrued      expenses                                                    |                    |   |   | $11,000 |   |   |   |   | $28,200 |   |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
| Total      Current Liabilities                                           |                    |   |   | 11,000 |   |   |   |   | 28,200 |   |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
|  STOCKHOLDERS'      DEFICIT:                                        |                    |   |   |   |   |   |   |   |   |   |
| Preferred      stock at $0.0001 par value: 1,000,000 shares authorized,  |                    |   |   |   |   |   |   |   |   |   |
| none      issued or outstanding                                          |                    |   |   | - |   |   |   |   | - |   |
| Common      stock at $0.0001 par value: 20,000,000 shares authorized,    |                    |   |   |   |   |   |   |   |   |   |
| 4,188,000      and 4,008,000 shares issued and outstanding, respectively |                    |   | 419 |   |   |   |   | 401 |   |
| Additional      paid-in capital                                          |                    |   |   | 46,581 |   |   |   |   | 1,599 |   |
| Deficit      accumulated during the development stage                    |                    |   |   | (57,629 | ) |   |   |   | (28,107 | ) |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
| Total      Stockholders' Deficit                                         |                    |   |   | (10,629 | ) |   |   |   | (26,107 | ) |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
| Total      Liabilities and Stockholders' Deficit                         |                    |   |   | $371 |   |   |   |   | $2,093 |   |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |
| See      accompanying notes to the financial statements.                 |                    |   |
|                                                                     |                    |   |
|                                                                     |                    |   |   |   |   |   |   |   |   |   |

----

| NOBLE      MEDICAL TECHNOLOGIES, INC.                    |                                            |
|----------------------------------------------------------|-------------------------------------------------|
| (A      DEVELOPMENT STAGE COMPANY)                       |                                            |
| STATEMENTS      OF OPERATIONS                            |                                            |
| (UNAUDITED)                                              |                                            |
|                                                     |                                            |   |   |   |   |   |   |   |   |
|                                                     |                                            |   |   |   |   | For      the Period from |   |
|                                                     |                                            | For      the Three Months |   | July      25, 2007 |   |
|                                                     |                                            | Ended |   | (Inception)      through |   |
|                                                     |                                            | September      30, 2008 |   | September      30, 2007 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |
|  OPERATING      EXPENSES:                           |                                            |   |   |   |   |   |   |   |
|                                                     |  Professional      fees                    |   |   |   | $2,000 |   |   |   |   | $- |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
|                                                     |  Total      operating expenses             |   |   |   | 2,000 |   |   |   |   | - |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
|  LOSS      BEFORE TAXES                             |                                            |   |   | (2,000 | ) |   |   |   | - |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
|  INCOME      TAXES                                  |                                            |   |   | - |   |   |   |   | - |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
|  NET      LOSS                                      |                                            |   |   | $(2,000 | ) |   |   |   | $- |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
|  NET      LOSS PER COMMON SHARE -                   |                                            |   |   |   |   |   |   |   |   |   |
|                                                     |  BASIC      AND DILUTED:                   |   |   |   | $(0.00 | ) |   |   |   | $0.00 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
|                                                     |  Weighted      Common Shares Outstanding - |   |   |   |   |   |   |   |   |   |
|                                                     |  basic      and diluted                    |   |   |   | 4,188,000 |   |   |   |   | 4,001,194 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
| See      accompanying notes to the financial statements. |                                            |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |

|   |
|--------|

----

| NOBLE      MEDICAL TECHNOLOGIES, INC.                    |                                            |
|----------------------------------------------------------|-------------------------------------------------|
| (A      DEVELOPMENT STAGE COMPANY)                       |                                            |
| STATEMENTS      OF OPERATIONS                            |                                            |
| (UNAUDITED)                                              |                                            |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                     |                                            |   |   |   |   | For      the Period from |   | For      the Period from |   |
|                                                     |                                            | For      the Nine Months |   | July      25, 2007 |   | July      25, 2007 |   |
|                                                     |                                            | Ended |   | (Inception)      through |   | (Inception)      through |   |
|                                                     |                                            | September      30, 2008 |   | September      30, 2007 |   | September      30, 2008 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |
|  OPERATING      EXPENSES:                           |                                            |   |   |   |   |   |   |   |   |   |   |   |
|                                                     |  Professional      fees                    |   |   |   | $18,750 |   |   |   |   | $- |   |   |   |   | $46,850 |   |
|                                                     |  General      and administrative expenses  |   |   |   | 9,972 |   |   |   |   | - |   |   |   |   | 9,979 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                     |  Total      operating expenses             |   |   |   | 28,722 |   |   |   |   | - |   |   |   |   | 56,829 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  LOSS      BEFORE TAXES                             |                                            |   |   | (28,722 | ) |   |   |   | - |   |   |   |   | (56,829 | ) |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  INCOME      TAXES                                  |                                            |   |   | 800 |   |   |   |   | - |   |   |   |   | 800 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  NET      LOSS                                      |                                            |   |   | $(29,522 | ) |   |   |   | $- |   |   |   |   | $(57,629 | ) |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  NET      LOSS PER COMMON SHARE -                   |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                     |  BASIC      AND DILUTED:                   |   |   |   | $(0.01 | ) |   |   |   | $0.00 |   |   |   |   | $(0.01 | ) |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                     |  Weighted      Common Shares Outstanding - |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                     |  basic      and diluted                    |   |   |   | 4,146,321 |   |   |   |   | 4,001,194 |   |   |   |   | 4,094,171 |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See      accompanying notes to the financial statements. |                                            |   |
|                                                     |                                            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

| NOBLE      MEDICAL TECHNOLOGIES, INC.                                              |   |
|------------------------------------------------------------------------------------|--------|
| (A      DEVELOPMENT STAGE COMPANY)                                                 |   |
| STATEMENT      OF STOCKHOLDERS' DEFICIT                                            |   |
| For      the Period from July 25, 2007 (Inception) through September 30,      2008 |   |
| (UNAUDITED)                                                                        |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   | Common      Stock, $0.001 Par Value |   |   | Additional |   |   | Deficit      accumulated |   |   | Total |   |
|                                                                               |   | Number      of |   |   |   |   |   | Paid-in |   |   | During      the |   |   | Stockholders' |   |
|                                                                               |   | Shares |   |   | Amount |   |   | Capital |   |   | Development      Stage |   |   | Deficit |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Balance,      July 25, 2007                                                  |   |   | - |   |   |   | $- |   |   |   | $- |   |   |   | $- |   |   |   | $- |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Issuance      of common stock to  founders                         |   |   | 4,000,000 |   |   |   | 400 |   |   |   | (400 | ) |   |   |   |   |   |   | - |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Issuance      of common stock for cash                                       |   |   | 8,000 |   |   |   | 1 |   |   |   | 1,999 |   |   |   |   |   |   |   | 2,000 |   |
| July      through December 2007 at $0.25 per share                                 |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net      loss                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (28,107 | ) |   |   | (28,107 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Balance,      December 31, 2007                                              |   |   | 4,008,000 |   |   |   | 401 |   |   |   | 1,599 |   |   |   | (28,107 | ) |   |   | (26,107 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Issuance      of common stock for cash                                       |   |   | 180,000 |   |   |   | 18 |   |   |   | 44,982 |   |   |   |   |   |   |   | 45,000 |   |
| January      through April 17, 2008 at $0.25 per share                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net      loss                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   | (29,522 | ) |   |   | (29,522 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Balance,      September 30, 2008                                             |   |   | 4,188,000 |   |   |   | $419 |   |   |   | $46,581 |   |   |   | $(57,629 | ) |   |   | $(10,629 | ) |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See      accompanying notes to the financial statements.                           |   |   |
|                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

| NOBLE      MEDICAL TECHNOLOGIES, INC.                    |                     |
|----------------------------------------------------------|--------------------------|
| (A      DEVELOPMENT STAGE COMPANY)                       |                     |
| STATEMENTS      OF CASH FLOWS                            |                     |
| (UNAUDITED)                                              |                     |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |
|                                                     |                     |   |   |   | For      the Period from |   | For      the Period from |   |
|                                                     | For      the Nine Months |   | July      25, 2007 |   | July      25, 2007 |   |
|                                                     | Ended                    |   | (Inception)      through |   | (Inception)      through |   |
|                                                     | September      30, 2008  |   | September      30, 2007 |   | September      30, 2008 |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |
| CASH      FLOWS FROM OPERATING ACTIVITIES:               |                     |   |   |   |   |   |   |   |   |
|  Net      loss                                      |                     |   |   | $(29,522 | ) |   |   |   | $- |   |   |   |   | $(57,629 | ) |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Adjustments      to reconcile net loss to net cash       |                     |   |   |   |   |   |   |   |   |   |   |
|  used      in operating activities                  |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Changes      in operating assets and liabilities:        |                     |   |   |   |   |   |   |   |   |   |   |
|  Accrued      expenses                              |                     |   |   | (17,200 | ) |   |   |   | - |   |   |   |   | 11,000 |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  NET      CASH USED IN                              |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  OPERATING      ACTIVITIES                          |                     |   |   | (46,722 | ) |   |   |   | - |   |   |   |   | (46,629 | ) |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| CASH      FLOWS FROM FINANCING ACTIVITIES:               |                     |   |   |   |   |   |   |   |   |   |   |
|  Sale      of common stock                          |                     |   |   | 45,000 |   |   |   |   | - |   |   |   |   | 47,000 |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  NET      CASH PROVIDED BY FINANCING ACTIVITIES     |                     |   | 45,000 |   |   |   |   | - |   |   |   |   | 47,000 |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  NET      CHANGE IN CASH                            |                     |   |   | (1,722 | ) |   |   |   | - |   |   |   |   | 371 |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Cash      at beginning of period                   |                     |   |   | 2,093 |   |   |   |   | - |   |   |   |   | - |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Cash      at end of period                         |                     |   |   | $371 |   |   |   |   | $- |   |   |   |   | $371 |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  SUPPLEMENTAL      DISCLOSURE OF                    |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  CASH      FLOW INFORMATION:                        |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Interest      paid                                 |                     |   |   | $- |   |   |   |   | $- |   |   |   |   | $- |   |
|  Taxes      paid                                    |                     |   |   | $800 |   |   |   |   | $- |   |   |   |   | $800 |   |
|                                                     |                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See      accompanying notes to the financial statements. |                     |   |

----

----

| ·   | of      management’s responsibility for establishing and maintaining adequate      internal control over its financialreporting; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| ·   | of      management’s assessment of the effectiveness of its internal control over      financial reporting as of year end;and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| ·   | of      the framework used by management to evaluate the effectiveness of the      Company’s internal control over financial  reporting. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

|   | Renting      and Furnishing      Offices                    $150,000                             $250,000 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | FDA      Compliance                                             $  15,000                             $  15,000 |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Equipment                                                        $  80,000                             $280,000 |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Officer      Salaries                                                $100,000                             $250,000 |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Marketing      Expense                                          $135,000                             $725,000 |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Working      Capital                                              $100,000                              $450,000 |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | None |
|--------|------|

----

----

| Exhibit      Number |  Exhibit      Description                                                                                                                                                     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1                 | Certificate      of Incorporation - Incorporated by reference to like numbered exhibit to      the Company’s Registration Statement on Form S-1 File Number      333-150483. |
| 3.2                 | Bylaws      - Incorporated by reference to like numbered exhibit to the Company’s      Registration Statement on Form S-1 File Number  333-150483.                           |
| 4.1                 | Specimen      Stock Certificate - Incorporated by reference to like numbered exhibit to      the Company’s Registration Statement on Form S-1 File Number      333-150483.   |
| 21                  | Description      of Subsidiaries. None                                                                                                                                             |
| 31.1                | Rule      13a-14(a)/15d-14(a) Certification by the Principal Executive Officer and      Principal Financial Officer.**                                                             |
| 32.2                | Section      1350 Certification by the Principal Executive Officer, Principal Financial      Officer and Principal AccountingOfficer.**                                            |

----

|   | Noble      Medical Technologies, Inc. |
|--------|---------------------------------------|

| Date:      September 14, 2008 | By: | /s/ Richard  Krutosik |
|-------------------------------|-----|-----------------------|

|   | Richard      Krutosik, President and CEO |
|--------|------------------------------------------|

----